Analyst Price Targets — SLNO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 11:41 am | Raghuram Selvaraju | H.C. Wainwright | $100.00 | $38.50 | StreetInsider | Soleno Therapeutics Inc. (SLNO) PT Lowered to $100 at H.C. Wainwright |
| January 20, 2026 11:19 am | Derek Archila | Wells Fargo | $114.00 | $42.48 | TheFly | Soleno Therapeutics price target raised to $114 from $106 at Wells Fargo |
| January 20, 2026 11:17 am | — | H.C. Wainwright | $120.00 | $42.48 | TheFly | Soleno Therapeutics price target raised to $120 from $110 at H.C. Wainwright |
| January 13, 2026 1:41 pm | — | Robert W. Baird | $107.00 | $40.14 | TheFly | Soleno Therapeutics price target lowered to $107 from $121 at Baird |
| January 12, 2026 6:52 pm | — | Wolfe Research | $60.00 | $41.89 | TheFly | Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research |
| November 5, 2025 11:26 am | Derek Archila | Wells Fargo | $106.00 | $63.85 | TheFly | Soleno Therapeutics price target lowered to $106 from $123 at Wells Fargo |
| October 7, 2025 8:48 am | — | Goldman Sachs | $125.00 | $58.45 | TheFly | Soleno Therapeutics initiated with a Buy at Goldman Sachs |
| July 11, 2025 11:18 am | Brian Skorney | Robert W. Baird | $121.00 | $81.57 | TheFly | Soleno Therapeutics price target raised to $121 from $105 at Baird |
| March 28, 2025 11:06 am | Debjit Chattopadhyay | Guggenheim | $81.00 | $70.22 | TheFly | Soleno Therapeutics price target raised to $81 from $70 at Guggenheim |
| March 27, 2025 5:13 pm | — | Robert W. Baird | $102.00 | $67.39 | TheFly | Soleno Therapeutics price target raised to $102 from $72 at Baird |
Latest News for SLNO
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets.
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Soleno Therapeutics (NASDAQ: SLNO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation. Analyst Ratings This is a breakdown of current
Emerald Advisers LLC lessened its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) by 6.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 627,756 shares of the company's stock after selling 45,152 shares during the quarter. Soleno
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLNO.
U.S. House Trading
No House trades found for SLNO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.